A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel

Gynecologic Oncology

Volumn 84, Issue 3, 2002, Pages 420-425

  Kwon, Janice S ^a   Elit, Laurie ^a,b   Finn, Martha ^b   Hirte, Holger ^b   Mazurka, John ^b   Moens, Francois ^b   Trim, Kristina ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Conventional oral steroid regimen; Hypersensitivity reaction; Single dose intravenous steroid

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; RANITIDINE;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036200913     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6546     Document Type: Article

References (18)

1. Paclitaxel (Taxol)
2. Hypersensitivity reactions from Taxol
3. Phase I trial of Taxol given as a 3-hour infusion every 21 days
4. Phase I trial of Taxol in patients with advanced cancer
5. Phase I study of Taxol administered as a short IV infusion daily for 5 days
6. A phase I pharmacokinetic study of Taxol given by a prolonged infusion without premedication
7. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
8. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
9. Taxol hypersensitivity: Rapid retreatment is safe and cost effective
10. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
11. Carboplatin and paclitaxel in ovarian carcinoma. A phase I study of the Gynecologic Oncology Group
12. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions
13. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
14. Paclitaxel-assoclated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Centre
15. Successful re-treatment with Taxol after major hypersensitivity reactions